KDL Medical Director Sue Richards chairs ACMG work group for revised guidelines on sequence variants

2015

Mar
28

KDL Medical Director Sue Richards chairs ACMG work group for revised guidelines on sequence variants

KDL Medical Director Sue Richards chaired a work group for American College of Medical Genetics and Genomics (ACMG) in 2013 comprising representatives from the ACMG, the Association for Molecular Pathology (AMP), and the College of American Pathologists to revisit and revise the standards and guidelines for the interpretation of sequence variants. The guidelines were published this month. Read the report here.

Previous Article Next Article

Back To List

More in

News and Events

Innovations in Testing

View All Tests

The Knight Cancer Institute at Oregon Health & Science University is a pioneer in the field of precision cancer medicine. The institute's director, Brian Druker, M.D., helped prove it was possible to shut down just the cells that enable cancer to grow. This breakthrough has made once-fatal forms of the disease manageable and transformed how cancer is treated. The OHSU Knight Cancer Institute is the only National Cancer Institute-designated Cancer Center between Sacramento and Seattle – an honor earned only by the nation's top cancer centers. It is headquarters for one of the National Cancer Institute's largest research collaboratives, SWOG, in addition to offering the latest treatments and technologies as well as hundreds of research studies and clinical trials.

Learn More

About UsNews & Events

KDL Medical Director Sue Richards chairs ACMG work group for revised guidelines on sequence variants

GeneTrails®Comprehensive Solid Tumor Panel

GeneTrails® Hematologic - Malignancies 220 Gene Panel

GeneTrails® Solid Tumor Fusion Gene panel

Genome-Wide DNA Methylation Array

Oncology Microarray - Targeted Gene and Region Panel

Inherited Cancer Panel

Quanitative Intracelluar Signaling Panel - Research Only

Chromosomal Microarray - Prenatal Diagnosis